The Senate Permanent Subcommittee on Investigations released data in January 2026 showing that Medicare Advantage prior authorization denial rates have continued rising despite regulatory pressure. UnitedHealthcare — the largest Medicare Advantage insurer in the country — denied 12.8% of prior authorization requests in 2024, with Humana and CVS Health Aetna not far behind. The same report documented that 80.7% of those denials were overturned on appeal when patients challenged them — a figure that illustrates both the flaws in the initial denial system and the near-total failure of most patients to exercise their right to appeal.
The backdrop matters. Medicare Advantage plans are private insurance companies paid a fixed amount per enrollee by the federal government to administer Medicare benefits. Prior authorization — requiring approval before a treatment, procedure, or post-acute placement can be covered — is the primary mechanism through which these companies manage their costs. The Senate report found that major insurers deployed AI algorithms, most notably UnitedHealthcare's nH Predict tool, to process these requests at scale. The algorithms compared patient profiles to population-level averages to generate denial recommendations. In many documented cases, patients were denied care that medical professionals unanimously agreed was necessary.
The consumers most directly affected are the 55% of Medicare-eligible seniors and disabled Americans who have chosen Medicare Advantage over traditional Medicare. They are affected most acutely when they need post-acute care — skilled nursing facility stays following hospitalizations, ongoing rehabilitation therapy, or specialist referrals for complex conditions. Discharge from a hospital to home when ongoing care is medically indicated is one of the most common denial scenarios, and one with the most immediate consequences for vulnerable patients.
Two developments in 2026 have changed the landscape. The CMS Interoperability and Prior Authorization Final Rule, effective January 1, 2026, now requires Medicare Advantage plans to provide a specific clinical reason for every denial rather than a generic category. This change is significant because it forces insurers to articulate exactly what argument your appeal needs to counter. At the same time, CMS launched the WISeR pilot — an AI-assisted prior authorization system for traditional Medicare in six states — which has generated its own controversy about algorithmic decision-making in coverage determinations.
If you or a family member receives a Medicare Advantage denial in 2026, the most important fact to understand is that you almost certainly have grounds to appeal — and that you are far more likely than not to win that appeal if you file one. Our complete guide to appealing Medicare Advantage denials walks through the five-level appeals process, what documentation to include, and how to request an expedited 72-hour review when health is at immediate risk. The 60-day appeal window begins the day the denial letter is dated, not when you receive it.
Congress has continued to pressure the largest insurers for additional data on denial methodologies. Multiple class action lawsuits against UnitedHealthcare remain in active litigation. The regulatory and legal environment in 2026 is more favourable to patients challenging prior authorization denials than at any point in Medicare Advantage's history — but that only translates to better outcomes for patients who actually file appeals.